Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021. The pre-recorded chat will be available from 6:00 am E.T. on January 11 and can be accessed via the company's website. The company focuses on developing therapies for immune-mediated diseases and has submitted a Biologics License Application (BLA) for its investigational drug, teplizumab, aimed at delaying type 1 diabetes. For more information, visit www.ProventionBio.com.

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a Biologics License Application (BLA) to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes in at-risk individuals. The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-participate-in-the-hc-wainwright-virtual-bioconnect-conference-301202297.html

SOURCE Provention Bio, Inc.

FAQ

When is Provention Bio participating in the BioConnect Conference?

Provention Bio will participate in the H.C. Wainwright BioConnect Conference from January 11-14, 2021.

What time will the fireside chat replay be available?

The replay of the fireside chat will be available starting at 6:00 am E.T. on January 11, 2021.

How can I access Provention Bio's fireside chat?

You can access the replay of Provention Bio's fireside chat on their website in the Events and Webcasts section.

What is teplizumab and its purpose?

Teplizumab is Provention Bio's lead investigational drug candidate aimed at delaying or preventing clinical type 1 diabetes in at-risk individuals.

Where can I find more information about Provention Bio?

More information about Provention Bio can be found on their website at www.ProventionBio.com.